About: Linsitinib     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatProteinKinaseInhibitors, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FLinsitinib

Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012.

AttributesValues
rdf:type
rdfs:label
  • Linsitinib (en)
  • Linsitinib (pt)
rdfs:comment
  • Linsitinib é uma droga experimental camndidata ao tratamento de vários tipos de câncer. É uma enzima inicidora do IGF-1R. Ela previne a proliferação celular. è de uso oral. Linsitinib está em Fase III de pesquisa para carcinoma de supra-renal e fase II para cancer pulmonar e ovariano. (pt)
  • Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012. (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Linsitinib.svg
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
thumbnail
ImageFile
  • Linsitinib.svg (en)
imagesize
OtherNames
  • OSI-906 (en)
PIN
has abstract
  • Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012. Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued. A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma. As of 2017, no clinical trials were in progress. (en)
  • Linsitinib é uma droga experimental camndidata ao tratamento de vários tipos de câncer. É uma enzima inicidora do IGF-1R. Ela previne a proliferação celular. è de uso oral. Linsitinib está em Fase III de pesquisa para carcinoma de supra-renal e fase II para cancer pulmonar e ovariano. (pt)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
alternative name
  • OSI-906 (en)
IUPAC name
  • (1s,3s)-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol (en)
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (62 GB total memory, 52 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software